BACKGROUND In patients with severe aortic stenosis at increased risk for surgery, self-expanding transcatheter aortic valve replacement (TAVR) is associated with improved 2-year survival compared with surgery.
T ranscatheter aortic valve replacement (TAVR) has been established as an alternative to surgical valve replacement (SAVR) in patients with severe aortic stenosis who are deemed suboptimal for surgery (1, 2) . We have previously shown that patients at increased surgical risk treated with self-expanding TAVR had superior clinical outcomes compared with surgery (3), a benefit that was sustained 2 years after the procedure (4) . We hypothesized that the reasons for this survival benefit were related to reduced periprocedural complications (3) , such as bleeding, acute kidney injury, postoperative atrial fibrillation, improved aortic valve hemodynamics (3), lower rates of prosthesis-patient mismatch (5) , and more rapid recovery with improved health status (6) using TAVR compared with SAVR.
Although we expected that these health benefits would be largely realized in the first year after aortic valve replacement, we found a further separation of the survival curves between 1 and 2 years after the procedure (from 4.8% at 1 year to 6.5% at 2 years) (4) . We postulated that early surgical complications might have had a sustained impact on the 2-year survival and stroke outcomes in the surgical group (4) .
The purpose of this analysis was to determine whether the clinical benefit of self-expanding TAVR compared with SAVR was sustained 3 years later, and to compare aortic valve hemodynamics in the 2 groups in order to detect signals for structural valve deterioration.
METHODS STUDY DESIGN. This multicenter, prospective, randomized, noninferiority trial conducted at 45 sites across the United States has been reported in detail elsewhere (3, 4) . An independent Clinical Events Committee adjudicated all major clinical events, and an independent data safety monitoring board provided study oversight (3, 4) . The institutional review board at each site approved the protocol. All patients provided written, informed consent for the procedure and follow-up evaluations for 5 years.
PATIENT SELECTION. Patient selection has been described previously in detail (3) . In brief, patients with severe aortic stenosis defined as an aortic valve area (AVA) of #0.8 cm 2 or an AVA index of #0.5 cm 2 /m 2 and either a mean gradient >40 mm Hg Heart Association (NYHA) functional class II or worse symptoms were eligible for the trial if both the local heart team and a national screening committee agreed they were at increased risk for SAVR.
Increased risk was defined as an estimated 30-day mortality risk 15% or greater and a combined 30-day surgical mortality and major morbidity risk less than 50%. Risk was assessed using the Society of Thoracic Surgeons predictors of mortality score and other factors associated with increased surgical risk described in previous publications (7, 8) .
Detailed inclusion and exclusion criteria have been
reported (3) . Life-threatening or major bleeding and acute kidney injury were more common in the SAVR group, whereas vascular complications, reintervention, and the need for new permanent pacemakers were more common in the TAVR group; the majority of these events occurred within the first 30 days. The incidence of valve endocarditis and aortic valve hospitalization were low and not different between the 2 groups ( Table 2 ). The incidence of NYHA functional class I and II heart failure symptoms were similar in both groups at 3 years (92.3% for TAVR and 91.1% for SAVR) (Figure 2 ). ECHOCARDIOGRAPHIC FINDINGS. Three-year aortic valve gradients were lower in transcatheter patients (mean aortic valve gradient 7.62 AE 3.57 mm Hg vs. 11.40 AE 6.81 mm Hg in surgical patients; p < 0.001) ( Table 3) , although moderate or severe aortic regurgitation was higher in transcatheter patients (6.8% vs. 0.0% in surgical patients; p < 0.001) ( Table 3) . In paired analysis, 3-year aortic valve gradients were also statistically lower in transcatheter patients (Figure 3) . In paired analysis, the moderate or severe AR was also higher in the transcatheter patients (7.1% vs. 0.0%; p < 0.001) (Figure 4 ).
There was no evidence of clinical valve thrombosis or structural valve deterioration in either group. The rates of worsening aortic valve gradients, defined as a >50% increase from 1 month to 3 years, were similar 
DISCUSSION
The results of this analysis demonstrate the sustained 3-year clinical benefit of self-expanding TAVR over SAVR in patients with aortic stenosis at increased risk for surgery. Coupled with reductions in all-cause mortality and stroke, self-expanding TAVR was also shown to have lower 3-year mean aortic valve gradients and larger effective orifice areas compared with SAVR, albeit with more total aortic regurgitation.
There were no differences in the occurrence of structural valve deterioration over time in the 2 groups. We believe that these findings support the use of self-expanding TAVR as the treatment of choice in patients at increased risk for surgery.
CLINICAL OUTCOMES AFTER TAVR. One randomized trial in patients treated with balloon-expandable TAVR and surgery showed comparable clinical outcomes in the 2 groups 5 years after the procedure (10).
Although an early (6-month) clinical benefit was suggested with balloon-expandable TAVR, mortality was similar in the 2 groups 1 year (11), 2 years (12) Table 1 . Self-Expanding TAVR Versus SAVR at 3 Years J U N E 7 , 2 0 1 6 : 2 5 6 5 -7 4 regurgitation after TAVR, which has been associated with suboptimal late clinical outcomes (13, 14) . The low incidence (6.8%) of moderate and severe residual aortic regurgitation in this study may not have Abbreviations as in Figure 1 . STUDY LIMITATIONS. It is uncertain whether the crimping-recrimping of the transcatheter valve will have an impact on long-term bioprosthesis durability.
We used an as-treated analysis population to account for potential differential dropout of patients who declined therapy after randomization, primarily open surgery; however, we did confirm that the mortality benefit at 3 years with TAVR was similar in the intention-to-treat cohort. The 3-year follow-up is limited and longer 10-year studies are needed to understand the longer-term durability in patients at lower risk with longer life expectancies. 
CONCLUSIONS
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